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ABSTRACT
Objectives To compare the effectiveness of dry needling 
(DN) versus percutaneous needle electrolysis (PNE) for 
improving the level of pain, function and quality of life 
(QoL) of patients suffering from plantar heel pain (PHP) 
provoked by myofascial trigger points.
Design A prospective, parallel- group, randomised 
controlled trial with blinded outcome assessment.
Setting A single treatment facility in the State of Kuwait.
Participants 118 participants were screened for 
eligibility. Of these, 102 participants were enrolled (30 men 
(49.5±8.9 years) and 72 women (48.1±8.8 years)) and 68 
of them completed the trial.
Interventions Two parallel groups, one study arm 
received DN and a stretching protocol whereas the other 
arm received percutaneous needling electrolysis with a 
stretching protocol.
Primary and secondary outcome measures The 
primary outcome measure was the Foot Pain domain of 
the Foot Health Status Questionnaire, with 13 questions 
related to foot health- related domains. Secondary 
outcome measures included the 0–10 numerical rating 
scale pain visual analogue scale (VAS) scores, performed 
before and after each treatment session. In addition, 
QoL was measured using the EuroQoL-5 dimensions. All 
measurements were taken at baseline, at 4, 8, 12, 26 and 
52 weeks.
Results Foot Pain domain improved at all time points for 
DN group (p<0.001; 29.7 (17.8 to 41.5)) and percutaneous 
needling electrolysis group (p<0.001; 32.7 (18.3 to 
47.0)), without significant differences between groups. 
Pain VAS scores decreased at all time points for both DN 
(p<0.001; −2.6 (−4.0 to −1.2)) and percutaneous needling 
electrolysis group (p<0.001; −3.0 (−4.5 to −1.6)). QoL 
improved at 4 weeks for both DN (p<0.01; 0.15 (0.5 
to 0.25)) and percutaneous needling electrolysis group 
(p<0.01; 0.09 (0.01 to 0.17)) and at 8 and 52 weeks 
for the PNE group (p<0.01; 0.10 (0.02 to 0.18)), with 
significant differences between groups for the QoL at 52 
weeks (p<0.05; 0.10 (0.01 to 0.18)). There were two small 
haematomas in the PNE group and one in the DN group. 
No serious adverse events were reported.
Conclusions Both PNE and DN were effective for PHP 
management, reducing mean and maximum pain since the 
first treatment session, with long lasting effects (52 weeks) 
and significant differences between groups in the case of 
QoL at 52 weeks in favour of the PNE group.
Trial registration number NCT03236779.
INTRODUCTION
Plantar heel pain (PHP) is a common problem 
affecting the foot, causing soreness or tender-
ness in the sole of the foot, and under the 
heel, sometimes extending into the medial 
arch.1 The frequency and incidence of PHP 
is uncertain; however, it is estimated that over 
the course of a lifetime 10% of the popula-
tion may suffer from this condition.2 3 Several 
pathologies may cause PHP, such as myofas-
cial pain syndrome, plantar fasciitis or heel 
spur, among others.4 The clinical diagnosis 
is usually established based on the patient’s 
history and physical examination, including 
pain during the first steps in the morning or 
after prolonged rest, as well as pain during 
prolonged standing or walking.2 3 5 The iden-
tification of the main cause of pain can be 
challenging as this is often multifactorial,6 
and despite its prevalence, the aetiology of 
PHP is not well understood.2 3 The presence 
of myofascial trigger points (MTrPs) within 
the muscles of the foot and lower leg may 
play an important role in people in PHP,7 an 
Strengths and limitations of this study
 ► This is the first randomised controlled trial compar-
ing the effectiveness of percutaneous needle elec-
trolysis with dry needling for plantar heel pain (PHP) 
provoked by myofascial trigger points (MTrPs), in-
volving a large sample and a long follow- up period.
 ► The assessor was blinded to group allocation for 
all assessments; however, neither the therapist nor 
the participants were blinded due to the difficulty of 
blinding investigators and participants when apply-
ing invasive treatment techniques.
 ► Due to the different potential causes of PHP, the re-
sults of this study are only valid if this is provoked 
by MTrPs.
 ► This is a single centre trial and results may not be 
generalisable.
 ► Due to the large number of drop- outs, our study had 
the limitation of being underpowered to report a dif-
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implicit assumption underlying many recent studies.8–11 
In addition, there is a lack of consensus regarding the 
ideal management approach for PHP.12–14
Clinical practice guidelines support the use of conser-
vative treatment, such as joint and soft tissue mobilisation 
or self- stretching home programmes.2 3 In particular, 
self- stretching home programmes have shown to be 
effective for addressing PHP.2 6 15 Furthermore, recent 
randomised clinical trials (RCTs) have shown that there 
is an additional effect of reduction of pain severity when 
self- stretching home programmes are combined with isch-
aemic compression11 and with dry needling (DN).9 Phys-
ical therapy approaches continue to evolve and include 
the combination of DN and electrolysis, known as percu-
taneous needle electrolysis (PNE), with promising results 
for the treatment of tendon pathologies.16–18 The PNE 
technique is a minimally invasive treatment that consists 
of the application of a galvanic electrolytic current that 
causes a controlled local inflammatory process in the 
target tissue. This promotes phagocytosis and the subse-
quent regeneration of the affected tissue.16 17 Currently, 
PNE is being used in clinical practice to manage MTrPs; 
however, there are no studies supporting any additional 
beneficial effects of the same over DN.
From a biological point of view, it seems reasonable 
to hypothesise that subjects may display improvements 
thanks to the mechanical effects of the needle, and that 
patients may experience superior benefits when the 
electrolysis effect is added to the mechanical stimulus 
provided by the needle. Therefore, the aim of this RCT 
was to compare the effectiveness of DN versus PNE for 
improving the level of pain, function and quality of life 
(QoL) of patients suffering from PHP caused by MTrPs.
METHODS
Design
This study was a prospective, parallel- group RCT with 
blinded outcome assessment. Participants were recruited 
from Kuwait City, Kuwait, and both the assessment and 
intervention were conducted at the Physical Medicine and 
Rehabilitation Hospital in Kuwait. The study protocol has 
been previously published19 and the trial is registered at 
Clinicaltrials. com. This RCT was reported in accordance 
with the Consolidated Standards of Reporting Trials state-
ment for non- pharmacological trials.
Participants
The study subjects were men and women, enrolled at the 
Physical Therapy Department of the Physical Medicine 
and Rehabilitation Hospital in Kuwait City. Participants 
were included if they fulfilled the following criteria: (1) 
diagnosed of PHP in accordance with the Clinical Guide-
lines linked to the International Classification of Func-
tion, Disability and Health from the Orthopedic Section 
of the American Physical Therapy Association2 3 8 9; (2) 
aged 21–60 years at admission to the study, according to 
the Kuwaiti Ethical Committee; (3) a history of PHP for 
over 1 month, showing no improvements with previous 
conservative treatment; (4) the ability to walk 50 m 
without any support; (5) the presence of MTrPs on plantar 
and calf muscles based on an initial physical examination 
carried out by a physiotherapist (MA) with experience 
and training in MTrPs; (6) accepting treatment from a 
male physiotherapist; (7) the ability to understand the 
study and the informed consent, as well as having signed 
the consent form.
The exclusion criteria were: (1) needle phobia; (2) 
needle allergy or hypersensitivity to metals; (3) the pres-
ence of coagulopathy or use of anticoagulants according 
to medical criteria; (4) the presence of peripheral arte-
rial vascular disease; (5) pregnancy; (6) dermatological 
disease affecting the DN area; (7) the presence of any 
chronic medical condition which might preclude partici-
pation in the study, such as: malignancy, systemic inflam-
matory disorders (eg, rheumatoid arthritis, psoriatic 
arthritis, ankylosing spondylitis, septic arthritis), neuro-
logical diseases, polyneuropathy, mononeuropathy and 
sciatica; (8) treatment of PHP with needling or acupunc-
ture during the last 4 weeks; (9) history of injection 
therapy in the heel over the previous 3 months; and (10) 
history of foot surgery or fracture. Receiving or imple-
menting any form of treatment for the PHP (taping, 
night splints, massage therapy or footwear modifications) 
during the trial was considered withdrawal criteria.
The sample- size calculation initially estimated that 
39 participants per group would provide 80% power to 
detect a minimally important difference of 13 points in 
the pain domain of the Foot Health Status Questionnaire 
(FHSQ) with a SD of 20 points20 and an alpha risk at 0.05. 
Allowing for a 20% loss to follow- up, a minimum of 47 
participants was required in each group, equalling 94 
participants in total. Based on initial data collection, the 
drop- out rate was recalculated to be 25% and the sample 
size was therefore increased to a total of 102 patients.
Patient and public involvement
No patients were involved in the design, recruitment or 
conduction of this study and the burden of the interven-
tion was not assessed by patients themselves neither.
Randomisation
Participants who fulfilled the inclusion criteria received 
standardised oral and written information, and, 
after consenting to participate in the trial, they were 
randomised using block randomisation by blocks of 
10 patients. Allocation was randomly assigned using a 
computer program (Randomizer, https://www. random-
izer. org/) with random patient file number sequences 
generated by a third person not involved in the study.
Procedure and interventions
Two study groups were randomly formed. The first was 
treated with DN whereas the second group was treated 
with PNE. In both groups, during the first session, all 
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has been demonstrated to be effective for the manage-
ment of PHP,2 6 11 consisting of self- stretching of the calf 
muscles and specific self- stretching for the plantar fascia.19 
The frequency of calf and plantar fascia- specific self- 
stretching exercises was two times a day, using intermit-
tent stretching lasting 20 s, followed by 20 s rest periods, 
for a total of 3 min per stretch.11 Compliance with the self- 
stretching protocol was registered before each treatment 
session and at the 4- week follow- up.
The muscles considered for invasive physical therapy 
treatment were the soleus, gastrocnemius, quadratus 
plantae, flexor digitorum brevis and abductor hallucis. 
These muscles typically refer pain to the heel and are 
muscles than can be directly palpated or that can be 
needled precisely and safely without ultrasound guid-
ance. The clinician performed a physical exam to find 
MTrPs following the criteria by Travell and Simons: (1) 
the presence of a taut band and (2) identification of an 
exquisite spot tenderness or a nodule.7 A flat palpation 
or pincer palpation technique was used to palpate the 
MTrPs, depending on the muscle being assessed. If a 
muscle contained more than one MTrP, the most sensitive 
MTrP was treated, according to the patient’s perceived 
pain on palpation. If the patient presented bilateral pain, 
the clinician treated both sides. The patient’s position 
(supine, prone or lateral decubitus position) depended 
on each muscle examined and was the same for the assess-
ment as well as for the intervention.
Each participant received four individual physical 
therapy sessions, once a week. Participants was treated by 
one physical therapist registered at the Kuwait Ministry 
of Health (ZA) with 5 years of practical experience in the 
field of DN and appropriate training in the protocol. The 
duration of each session was approximately 30 min.
Participants were instructed to use the appropriate 
dose of medication as prescribed by their Physical Medi-
cine and Rehabilitation physician (analgesics and non- 
steroidal anti- inflammatory medications) and were 
required to report any changes to the assessor during 
the evaluations if they took any additional medication or 
underwent any treatment during the intervention.
Invasive intervention groups: DN and PNE
Specific needles for DN were used during invasive treat-
ments (Agu- punt, Spain). Needle length was deter-
mined by the location of the MTrP and ranged from 30 
to 75 mm in length (or longer if necessary, according to 
the patients’ characteristics). The diameter of the needle 
was 0.25–0.30 mm. If the participant was sensitive to the 
needle insertion, the level of manipulation was reduced. 
If this measure proved insufficient for reducing the 
painful stimulus, needle manipulation ceased altogether 
and the needle was left in situ.21 22
To maintain appropriate hygienic conditions during 
the invasive treatments, the clinician wore latex gloves 
and thoroughly cleaned the skin of the area to be needled 
with an antiseptic solution (70% Propan-2- ol, Skin- des). 
On removal of the needle, the area was firmly compressed 
for 10 s. The needle was discarded after each single use. 
In both groups, the intervention was terminated in the 
case of severe adverse effects and if the participant did 
not wish to continue.
DN arm
Once the clinician located the MTrP, the needle was 
inserted over the same and a rapid needle entry was 
performed. The chosen technique for manipulating 
the needle was the technique described by Hong, which 
consists of a rapid needle entry and exit (fast in/fast 
out), in order to obtain a local twitch response, lasting 5 s 
employing a rhythmic movement at approximately 1 Hz/s 
(five entries).
PNE arm
The electrotherapy equipment used (Physio Invasiva, 
PRIM Fisioterapia, Spain) produced a continuous 
galvanic current through the cathode while the patient 
held a hand- held anode.18 Once the needle reached the 
relevant treatment area, this was needled in exactly the 
same manner as in the DN group, with the only differ-
ence being that the needle was transmitting an elec-
trical current with an intensity of 1.5 mA (intensity was 
adapted to patient’s characteristics according to their 
pain tolerance).
Study variables
An independent assessor (MA) blinded to treatment 
group allocation conducted all assessments at baseline, 
and at the 4, 8, 12, 26 and 52- week follow- up. Demo-
graphic and disease data were collected at baseline.
The primary outcome was the Foot Pain domain of 
the FHSQ, a validated measure of foot- health status23 
that has been used in similar trials, which evaluated the 
effectiveness of different interventions for PHP.8 24 25 Indi-
vidual item scores were inserted into a computer program 
(FHSQ V.1.03) which, after data transformation, provides 
a score ranging from 0 to 100 for each domain,26 with 
greater scores reflecting a better condition.27
Secondary outcomes were the Foot Function, Footwear 
and General Foot Health (GFH) domains of the FHSQ, 
as well as the average and maximum level of pain over 
the past 48 hours using the visual analogue scale (VAS). 
Participants were explained that a score of 0 indicated the 
absence of pain whereas a score of 10 represented the 
maximum tolerable pain. Additionally, before each treat-
ment session, they were asked to complete the VAS and 
after each treatment session, participants were asked to 
score their current pain immediately on standing up and 
walking a few steps. The VAS is widely used and is both 
valid and reliable.28–30
Quality of life (QoL) was assessed with the EQ- 5D- 5L, 
which was completed by the participants at baseline and 
at the 4, 8, 12, 26 and 52- week assessments. The EQ- 5D- 5L 
self- report questionnaire is a descriptive system with five 
questions, each representing one dimension of health- 















pen: first published as 10.1136/bm





4 Al- Boloushi Z, et al. BMJ Open 2020;10:e038033. doi:10.1136/bmjopen-2020-038033
Open access 
pain/discomfort and depression/anxiety. Each dimen-
sion can be rated on five levels: no problems, slight prob-
lems, moderate problems, severe problems and extreme 
problems. Together, the results serve to classify people 
into 1 of 3125 possible health states.31 These health states 
are subsequently transformed to QoL values with the 
EQ- 5D- 5L crosswalk value sets.32
Statistical analysis
The statistical analysis was performed using IBM SPSS 
Statistics (V.25, IBM) by intention to treat, with the 
last observation carried forward. The investigator who 
performed the analyses was masked to group allocation. 
The significance level for all statistical tests was set at 
p≤0.05.
χ2 tests were used to analyse if there were differences in 
categorical variables between groups at baseline. In addi-
tion, independent Student’s t- tests and Mann- Whitney U 
tests were used for parametric and non- parametric quan-
titative variables, respectively. χ2 tests were used to eval-
uate the compliance of the self- stretching protocol.
Following recommendations to estimate treatment 
effects in RCTs, linear mixed models adjusted for base-
line values were used to test the mean effect of treatment 
interventions at the follow- up at the 4, 8, 12, 26 and 
52 weeks, for the FHSQ and EQ- 5D- 5L measures. Linear 
mixed models adjusted for baseline values were used to 
test the mean effect of treatment interventions at the 
second session, third session, fourth session, and at the 
4, 8, 12, 26 and 52- week follow- ups, for measures of VAS 
(average and maximum). Individual repeated measures 
(RM) ANOVAs were used to test time effects within each 
treatment group for primary and secondary outcomes. 
Cross- sectionally, at all linear mixed models and RM- A-
NOVAs, the Bonferroni correction was used to test 
between- group time point differences or within- group 
time changes, respectively. The Greenhouse- Geisser 
correction was applied for correcting against violations of 
sphericity, whereas eta- squared (η²) was used to estimate 
the magnitude of the difference between both groups 
(0.01 small effect, 0.06 medium effect and 0.14 large 
effect).33 Independent t- tests were used to determine any 
difference between groups for measures of level of pain 
immediately after each treatment session.
RESULTS
Recruitment commenced in January 2018 and was 
completed by October 2018. One hundred and eighteen 
potential participants were screened for inclusion and 102 
participants were enrolled and randomly allocated to each 
of the treatment interventions. In total, 79 participants 
(78%) completed the four treatment sessions and were 
assessed at 4 weeks, 78 participants (77%) completed the 
8- week follow- up, 76 (75%) participants completed the 
12- week follow- up, 75 (74%) participants completed the 
26- week follow- up and 68 (67%) participants completed 
the 52- week follow- up (figure 1). The mean time between 
each treatment session was 7.0 days (SD 1.1) for the DN 
group and 6.9 days (SD 1.2) for the PNE group.
The mean age of participants was 48.8 years (SD 8.8; 
range 24–60) and 71% were women. The mean duration 
of PHP was 7.9 months (SD 9.3; range 1–36). Both groups 
were similar for all baseline variables except for the 
consumption of medication for hypercholesterolaemia 
(p=0.012) (table 1).
There were two small haematomas in the PNE group 
and one in the DN group. No serious adverse events were 
reported. All withdrawals during the treatment period 
were due to an inability to withstand the pain related to 
needle insertion and stimulation of MTrPs. Nine with-
drawals were registered during the follow- up, as these 
participants received other treatments during the study 
period (non- compliance of receiving other treatment).
The frequencies of protocol compliance with self- 
stretching did not differ between groups (χ2(4)=1.13, 
p=0.890) (table 2).
Regarding the primary outcome measure, there was no 
group×time interaction for Foot Pain, although individual 
RM- ANOVA showed a significant effect of time in both 
groups, with lower scores at baseline than at follow- up for 
all time points in the DN group (p<0.001; 29.7 (17.8 to 
41.5)) and the PNE group (p<0.001; 32.7 (18.3 to 47.0)) 
(table 3).
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Individual RM- ANOVAs also showed a significant effect 
of time in both groups for Foot Function (DN: p<0.001; 
PNE: p<0.001), Footwear (DN: p=0.031; PNE: p<0.001), 
GFH (DN: p<0.001; PNE: p<0.001), EQ- 5D- 5L (DN: 
p=0.002; PNE: p=0.002), VAS- average (DN: p<0.001; 
PNE: p<0.001) and VAS- maximum (DN: p<0.001; PNE: 
p<0.001) (table 3).
Regarding the different timelines for the secondary 
outcome measurements, Foot Function improved in 
the PNE group at 8 weeks (p=0.002; 20.3 (5.1 to 35.5)) 
and at 52 weeks (p=0.001; 22.5 (6.6 to 38.4)), although 
without differences between groups. Footwear scores also 
had a significant improvement at 52 weeks in the PNE 
group (p<0.001; 23.5 (8.9 to 38.1)), without differences 
between groups. Regarding the QoL, there was a signif-
icant improvement at 8 weeks (p=0.035; 0.07 (0.01 to 
0.13)) and 52 weeks (p=0.003; 0.10 (0.02 to 0.18)) in the 
PNE group, with differences between groups in favour of 
the PNE group only at 52 weeks (p=0.032; 0.10 (0.01 to 
0.18)) (table 3).
Regarding pain, the DN intervention provided a 
benefit over PNE for VAS average (p=0.009; −1.36 (−2.37 
to 0.35)) and VAS maximum (p=0.043; −1.28 (−2.53 to 
−0.04)) at 4 weeks (table 4).
Table 5 shows the most frequently treated muscles. The 
level of pain just after each treatment session according 
to the VAS did not differ between groups (table 6).
DISCUSSION
Important clinical improvements were observed in both 
groups20 for the Foot Pain and GFH domains of the 
FHSQ at all time points. However, Foot Function and QoL 
did not follow the same pattern as the aforementioned 
domains. Thus, clinically significant improvements were 
observed at 4 weeks in both groups; however, at 8 weeks 
and 52 weeks, improvements were only observed in 
the PNE group. Furthermore, at 52 weeks, differences 
between groups were only found for QoL. These findings 
suggest a trend in the group receiving PNE, producing 
longer lasting effects regarding Foot Function and QoL 
compared with DN. Although there were statistically 
significant differences in QoL, there is no consensus of 
what the minimum clinically important difference is, 
which ranges from 0.03 to 0.5434
Table 1 Baseline characteristics of participants by 
intervention group
DN (n=51) PNE (n=51)
Age, years 49.5 (8.9) 48.1 (8.8)
Sex, n (%), male 15 (29.4) 15 (29.4)
Height, cm 160.5 (8.2) 161.2 (7.9)
Weight, kg 87.5 (16.5) 90.8 (15.2)
BMI, kg/m2 33.9 (5.5) 35.1 (6.4)
Duration of symptoms, months 6.0 (6.0) 9.9 (11.5)
Affected side, n (%)
  Right 14 (27.5) 16 (31.4)
  Left 13 (25.5) 20 (39.2)
  Bilateral 24 (47.1) 15 (29.4)
  Non- medicated, n (%) 11 (21.6) 15 (29.4)
Medications, n yes (%)
  Neuromodulators/antiepileptic 18 (35.3) 22 (43.1)
  Painkillers 16 (31.4) 16 (31.4)
  Anti- inflammatory medication 16 (31.4) 17 (33.3)
  Myorelaxant medication 9 (17.6) 8 (15.7)
Systemic medications, n yes (%)
  Hypercholesterolaemia 
medication
12 (23.5) 3 (5.9)
  Hypertension medication 14 (27.5) 8 (15.7)
  Diabetes mellitus medication 14 (27.5) 10 (19.6)
  Osteoarthrosis medication 3 (5.9) 4 (7.8)
  Lung disease medication 3 (5.9) 3 (5.9)
  Hormonal therapy 5 (9.8) 7 (13.7)
  Antidepressant medication 1 (2.0) 0 (0.0)
  Diet supplements 8 (15.7) 13 (25.5)
Previous treatments, yes (%)
  Corticosteroid injections 4 (7.8) 10 (19.6)
  ESWT 9 (17.6) 9 (17.6)
  Exercise 4 (7.8) 6 (11.8)
  Pain, FHSQ (100–0) 38.8 (18.8) 40.4 (21.9)
  Function, FHSQ (100–0) 57.2 (34.9) 55.5 (36.3)
  Shoe, FHSQ (100–0) 30.7 (35.3) 32.4 (35.9)
  GFH, FHSQ (100–0) 14.3 (18.2) 19.2 (23.7)
  VAS mean (0–10) 6.0 (2.3) 5.9 (2.4)
  VAS maximum (0–10) 7.6 (2.0) 7.5 (2.3)
Values are expressed in mean (SD) unless stated.
*P<0.05, significant differences between groups.
BMI, body mass index; DN, dry needling; ESWT, extracorporeal 
shock- wave therapy; FHSQ, Foot Health Status Questionnaire 
(0 corresponds to the worst foot health; 100, the best); GFH, 
General Foot Health; PNE, percutaneous needle electrolysis; 
VAS, visual analogue scale (0 corresponds to absence of pain; 
10, maximum tolerable pain).
Table 2 Frequencies of compliance with self- stretching 
protocol achieved in the DN and PNE groups
DN PNE
Four full weeks complied 11 (22%) 10 (20%)
Three full weeks complied 6 (12%) 4 (8%)
Two full weeks complied 6 (12%) 9 (18%)
One full week complied 9 (18%) 10 (20%)
Any full week complied 19 (37%) 18 (35%)
Values represent the number of participants (relative frequencies) 
for each compliance category of the 4 weeks self- stretching 
protocol.
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Table 3 Mean scores, mean change within group and mean difference between groups for FHSQ and EQ- 5D- 5L at baseline, 
week 4, week 8, week 12, week 26 and week 52
Variable DN mean (SD)














Foot Pain, FHSQ (100–0)
  Baseline 38.8 (18.8) 40.4 (21.9)
  Week 4 73.4 (27.7)‡ 34.6 (21.7 to 47.5) 71.9 (25.7)‡ 31.5 (18.7 to 44.2) −2.0 (−12.2 to 8.3) 0.707 (0.001)
  Week 8 70.1 (28.4)‡ 31.4 (17.5 to 45.3) 67.4 (26.8)‡ 27.0 (13.9 to 40.1) −3.1 (−13.8 to 7.6) 0.567 (0.003)
  Week 12 66.8 (24.8)‡ 28.1 (16.2 to 39.9) 63.6 (26.1)‡ 23.1 (10.6 to 35.6) −3.8 (−13.6 to 5.9) 0.437 (0.006)
  Week 26 68.8 (25.3)‡ 30.0 (18.1 to 42.0) 67.1 (27.1)‡ 26.7 (12.0 to 41.3) −2.0 (−12.3 to 8.3) 0.700 (0.002)
  Week 52 68.4 (25.1)‡ 29.7 (17.8 to 41.5) 73.1 (29.0)‡ 32.7 (18.3 to 47.0) 4.3 (−6.3 to 14.8) 0.424 (0.006)
  Main effect of 
time; p value
<0.001 <0.001   
Foot Function, FHSQ (100–0)
  Baseline 57.2 (34.9) 55.5 (36.3)
  Week 4 79.4 (31.2)‡ 22.2 (6.5 to 37.9) 71.7 (32.4)‡ 16,2 (0,5 to 31,8) −7.1 (−18.4 to 4.3) 0.220 (0.015)
  Week 8 72.7 (30.1) 15.4 (−1.3 to 32.2) 75.9 (29.7)‡ 20.3 (5.1 to 35.5) 3.7 (−7.5 to 14.7) 0.502 (0.005)
  Week 12 65.7 (31.7) 8.5 (−8.6 to 25.5) 71.1 (29.8) 15.6 (−0.7 to 31.8) 5.9 (−5.6 to 17.3) 0.311 (0.010)
  Week 26 70.2 (29.6) 13.0 (−4.5 to 30.4) 70.7 (28.8) 15.2 (−0.9 to 31.3) 0.9 (−10.1 to 11.9) 0.871 (0.001)
  Week 52 69.8 (29.6) 12.6 (−4.9 to 30.1) 78.0 (30.2)‡ 22.5 (6.6 to 38.4) 8.6 (−2.6 to 19.9) 0.132 (0.023)
  Main effect of 
time; p value
<0.001 <0.001   
Footwear, FHSQ (100–0)
  Baseline 30.7 (35.3) 32.4 (35.9)
  Week 4 35.0 (35.9) 4.2 (−10.5 to 19.0) 30.2 (33.9) −2.1 (−16.1 to 11.9) −5.6 (−17.1 to 5.9) 0.333 (0.009)
  Week 8 37.6 (34.2) 6.9 (−7.3 to 21.0) 30.1 (35.4) −2.3 (−18.9 to 14.3) −8.3 (−20.3 to 3.7) 0.174 (0.019)
  Week 12 41.0 (32.1) 10.3 (−3.7 to 24.3) 35.8 (35.9) 3.4 (−13.0 to 19.9) −6.0 (−17.8 to 5.8) 0.316 (0.010)
  Week 26 43.3 (32.7) 12.6 (−1.9 to 27.0) 39.0 (35.8) 6.7 (−9.1 to 22.5) −5.0 (−16.8 to 6.7) 0.397 (0.007)
  Week 52 44.2 (31.3) 13.4 (−1.6 to 28.5) 55.9 (35.7)‡ 23.5 (8.9 to 38.1) 10.9 (−0.5 to 22.3) 0.061 (0.035)
  Main effect of 
time; p value
0.015 <0.001   
GFH, FHSQ (100–0)
  Baseline 14.3 (18.2) 19.2 (23.7)
  Week 4 59.9 (34.4)‡ 45.5 (30.4 to 60.7) 53.3 (37.0)‡ 34.1 (19.4 to 48.9) −9.4 (−22.7 to 3.9) 0.165 (0.019)
  Week 8 54.6 (34.4)‡ 40.2 (25.4 to 55.1) 51.6 (35.2)‡ 32.4 (16.5 to 48.2) −5.2 (−18.5 to 8.2) 0.445 (0.006)
  Week 12 49.5 (33.5)‡ 35.1 (21.3 to 49.0) 53.6 (34.4)‡ 34.4 (20.1 to 48.6) 1.1 (−11.4 to 13.6) 0.860 (0.001)
  Week 26 54.7 (34.3)‡ 40.4 (26.0 to 54.8) 58.7 (34.9)‡ 39.5 (23.3 to 55.6) 1.8 (−11.4 to 15.1) 0.785 (0.001)
  Week 52 54.7 (34.3)‡ 40.4 (26.0 to 54.8) 66.4 (38.6)‡ 47.2 (30.1 to 64.2) 9.2 (−4.7 to 23.2) 0.190 (0.017)
  Main effect of 
time; p value
<0.001 <0.001   
EQ- 5D- 5L (1–0)
  Baseline 0.63 (0.23) 0.67 (0.22)
  Week 4 0.78 (0.22)‡ 0.15 (0.05 to 0.25) 0.76 (0.24)‡ 0.09 (0.01 to 0.17) −0.04 (−0.12 to 0.03) 0.265 (0.013)
  Week 8 0.72 (0.23) 0.09 (−0.03 to 0.21) 0.74 (0.23)‡ 0.07 (0.01 to 0.13) −0.01 (−0.08 to 0.07) 0.889 (0.001)
  Week 12 0.64 (0.30) 0.02 (−0.11 to 0.15) 0.70 (0.26) 0.03 (−0.05 to 0.11) 0.03 (−0.07 to 0.12) 0.587 (0.003)
  Week 26 0.65 (0.29) 0.02 (−0.10 to 0.14) 0.73 (0.27) 0.06 (−0.03 to 0.14) 0.05 (−0.04 to 0.14) 0.276 (0.012)
  Week 52 0.66 (0.27) 0.02 (−0.10 to 0.14) 0.77 (0.25)‡ 0.10 (0.02 to 0.18) 0.10 (0.01 to 0.18) 0.032 (0.045)§
  Main effect of 
time; p value
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Variable DN mean (SD)














Positive between group differences represent greater change (improvement) in the PNE group compared with the DN group.
*P value after Bonferroni’s correction between group.
†Eta- squared (η²); between groups effect size.
‡P<0.05 after Bonferroni’s correction comparing follow- up against baseline scores within group.
§P<0.05, significant differences between groups.
DN, dry needling; EQ- 5D- 5L, 0 corresponds to the worst quality of life; 1, the best; FHSQ, Foot Health Status Questionnaire (0 corresponds to the 
worst foot health; 100, the best); GFH, General Foot Health; PNE, percutaneous needle electrolysis.
Table 3 Continued
Table 4 Mean scores, mean change within group and mean difference between groups for VAS at baseline/1st session, 2nd 



















  Baseline/1st 
session
6.0 (2.3) 5.9 (2.4)
  2nd session 4.6 (2.2)‡ −1.4 (−2.5 to −0.3) 4.4 (2.7)‡ −1.5 (−2.5 to −0.5) 0.14 (−0.64 to 0.92) 0.725 (0.001)
  3rd session 4.0 (2.4)‡ −2.0 (−3.3 to −0.7) 4.1 (2.8)‡ −1.8 (−3.1 to −0.5) 0.16 (−1.11 to 0.79) 0.743 (0.001)
  4th session 3.5 (2.5)‡ −2.6 (−3.9 to −1.2) 3.4 (2.7)‡ −2.5 (−3.8 to −1.1) 0.01 (−0.95 to 0.97) 0.984 (0.001)
  Week 4 2.6 (2.5)‡ −3.5 (−4.9 to −2.0) 3.8 (3.0)‡ −2.0 (−3.2 to −0.8) −1.36 (−2.37 to 0.35) 0.009 (0.067)§
  Week 8 3.3 (2.8)‡ −2.7 (−4.2 to −1.2) 3.8 (2.7)‡ −2.1 (−3.4 to −0.8) −0.54 (−1.57 to 0.49) 0.298 (0.011)
  Week 12 3.3 (2.7)‡ −2.7 (−4.2 to −1.2) 3.7 (2.8)‡ −2.1 (−3.6 to −0.7) −0.46 (−1.51 to 0.58) 0.381 (0.008
  Week 26 3.4 (2.8)‡ −2.6 (−4.0 to −1.2) 3.4 (2.7)‡ −2.5 (−3.8 to −1.1) −0.06 (−0.97 to 1.09) 0.911 (0.001)
  Week 52 3.4 (2.8)‡ −2.6 (−4.0 to −1.2) 2.8 (3.0)‡ −3.0 (−4.5 to −1.6) 0.508 (−0.57 to 1.58) 0.351 (0.009)




  Baseline/1st 
session
7.6 (2.0) 7.5 (2.3)
  2nd session 6.2 (2.3)‡ −1.3 (−2.3 to −0.3) 5.5 (2.9)‡ −2.0 (−3.0 to −0.9) 0.66 (−0.18 to 1.50) 0.122 (0.024)
  3rd session 5.4 (2.6)‡ −2.2 (−3.6 to −0.8) 5.3 (3.1)‡ −2.2 (−3.6 to −0.8) 0.05 (−1.03 to 1.13) 0.926 (0.001)
  4th session 4.9 (2.9)‡ −2.7 (−4.1 to −1.3) 4.5 (3.0)‡ −3.0 (−4.4 to −1.6) 0.31 (−0.76 to 1.39) 0.563 (0.003)
  Week 4 3.6 (3.2)‡ −3.9 (−5.5 to −2.3) 4.9 (3.5)‡ −2.6 (−4.1 to −1.1) −1.28 (−2.53 to −0.04) 0.043 (0.041)§
  Week 8 4.7 (3.4)‡ −2.8 (−4.5 to −1.2) 5.0 (3.1)‡ −2.5 (−3.8 to −1.2) −0.32 (−1.50 to 0.87) 0.599 (0.003)
  Week 12 4.7 (3.3)‡ −2.9 (−4.5 to −1.3) 5.1 (3.1)‡ −2.4 (−3.9 to −1.0) −0.42 (−1.63 to 0.78) 0.487 (0.005)
  Week 26 4.5 (3.2)‡ −3.0 (−4.6 to −1.4) 4.6 (3.1)‡ −2.9 (−4.5 to −1.2) −0.13 (−1.34 to 1.09) 0.838 (0.001)
  Week 52 4.5 (3.2)‡ −3.0 (−4.6 to −1.4) 4.1 (3.4)‡ −3.4 (−5.1 to −1.8) 0.45 (−0.80 to 1.70) 0.480 (0.005)
  Main effect of 
time; p value
<0.001 <0.001
Positive between group differences represent greater change (improvement) in the PNE group compared with the DN group.
*P value after Bonferroni’s correction between group.
†Eta- squared (η²); between groups effect size.
‡P<0.05 after Bonferroni’s correction comparing follow- up against baseline scores within group.
§P<0.05, significant differences between groups.
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Patients allocated to both groups also had clinically 
important improvements in their mean and maximum 
level of pain since week 1 and during the 52 weeks of 
follow- up.35 There were differences between groups after 
4 weeks of treatment in favour of the DN group; however, 
this difference was not maintained over the time. Both 
groups had similar results to those reported by Cotchett et 
al8 at 4 weeks. However, at 12 weeks, although significant 
improvements were found in both groups, these findings 
differed from the aforementioned study, which we believe 
may be due to a higher number of drop- outs.
Clinical implications
Clinical implications may vary as it is possible that this 
study was underpowered. The sample size necessary to 
avoid this was a total of 78 patients at the end of the study, 
therefore, once we realised that the drop- out rate was 
higher than initially estimated, we increased the recruited 
patients from 94 (considering a 20% of drop- outs) to 102 
(considering a 25% of drop- outs). Despite this, in week 
12 and the following weeks, the number of patients were 
lower than the necessary to avoid underpowering, which 
could result in not detecting the treatment effect in week 
12 or later. For this reason, we carried out a per- protocol 
analysis and compared the results with the intention to 
treat analysis, which was more conservative, revealing 
similar results for both analyses. In addition, we analysed 
whether there were any results in week 8 that were not 
maintained, which was observed in Foot Function and 
QoL, revealing significant improvements at week 8 and 
week 52 for the percutaneous electrolysis group. Although 
it is speculative, either underpowering or the intention to 
treat analysis may explain the inconsistency of the results 
in the percutaneous electrolysis group, possibly leading 
to significant results in weeks 12 and 26.
From a clinical point of view, both groups reported 
similar levels of pain after the treatment, therefore, both 
treatment options should be considered to be equal in 
terms of pain tolerance or sensitisation after treatment. 
Apart from the minimal clinically important difference, 
it is also important to consider the patient acceptable 
symptomatic state (PASS) which provides the basis for 
determining whether the treatment enabled patients to 
achieve a satisfactory state and which may be a clinically 
relevant treatment target. In our study, we found that in 
both groups the average pain, measured using the VAS 
was 5 below points since the first session, which fulfils 
the PASS values determined in populations with similar 
sociocultural characteristics,36 despite the fact that this 
value was found to be unexpectedly high (50 mm) when 
compared with other populations.
The 118 initially selected patients presented MTrPs on 
plantar and calf muscles, as this was part of our inclu-
sion criteria, meaning that MTrPs could be directly or 
indirectly contributing to PHP. However, we were unable 
to find any previous study on the prevalence of MTrPs 
in patients with PHP. Therefore, future studies should 
consider following this line of research.
Strengths and limitations
This study presents several strengths and limitations. One 
of the strengths is that this is the first RCT to analyse 
the effectiveness of PNE and to compare it with DN for 
PHP caused by MTrPs, with a large sample size and a 
long follow- up. Several limitations should be noted. First, 
other sources of pain were not considered, as the study 
was designed to analyse the contribution of MTrPs in PHP. 
Furthermore, we did not measure the number of local 
twitch responses, which is a controversial factor, poten-
tially affecting the treatment effectiveness of MTrPs.37 
Besides, 23 patients (22.5%) dropped out of the study 
during the intervention as they were unable to tolerate 
pain, which is a higher drop- out rate compared with 
other studies.8 38–40 After the intervention period, drop- 
outs increased progressively to 24 at 8 weeks (23.5%), 
26 at 12 weeks (25.5%), 27 at 26 weeks (26.5%) and 34 
at 52 weeks (33.3%) of follow- up, which is similar to the 
study published by Taşoğlu et al,40 with 27.7% of drop- outs 
at 12 weeks. However, these rates differ with other previ-
ously mentioned studies.8 38 39 These differences may be 
due to the cultural behaviours towards pain in the region, 
which constitutes a limitation and an important chal-
lenge that must be addressed by clinicians. It is important 
to note that both treatments were safe with minimal side 
effects, such as haematoma or bruising, which is in line 
with other published studies revealing a low incidence of 
adverse effects.41
Table 5 Localisation and frequency of myofascial trigger 




Quadratus plantae 122 105
Flexor digitorum brevis 106 92
Abductor hallucis 102 93
Values represent the number of myofascial trigger points needled 
per muscle over the course of the study.
DN, dry needling; PNE, percutaneous needle electrolysis.







1st session 3.1 (2.9) 3.5 (2.6) 0.459
2nd session 3.1 (2.8) 3.1 (2.6) 0.968
3rd session 2.9 (2.6) 3.3 (3.2) 0.419
4th session 2.2 (2.7) 2.4 (2.6) 0.792
*P value after independent t- test.
DN, dry needling; PNE, percutaneous needle electrolysis; VAS, 
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CONCLUSIONS
Both PNE and DN were effective for PHP management, 
with long lasting effects (52 weeks) for Foot Pain and 
the GFH scores, without differences between groups. 
Besides, both treatments were found to be effective for 
reducing mean and maximum pain since the first treat-
ment session, with differences between groups in favour 
of DN group at 4 weeks only.
Although Foot Function and QoL also improved at 
4 weeks for both intervention groups, the PNE group 
showed improvements at 8 weeks and 52 weeks, with 
significant differences between groups in the case of QoL 
at 52 weeks.
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